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Effective adaptive immune responses depend on activation of
CD4 T cells via the presentation of antigen peptides in the
context of major histocompatibility complex (MHC) class II.
The structure of an antigen strongly influences its processing
within the endolysosome and potentially controls the identity of
peptides that are presented to T cells. A recombinant immuno-
toxin, comprising exotoxin A domain III (PE-III) from Pseu-
domonas aeruginosa and a cancer-specific antibody fragment,
has been developed to manage cancer, but its effectiveness is
limited by the induction of neutralizing antibodies. Here, we
observed that this immunogenicity is substantially reduced by
substituting six residues within PE-III. Although these substitu-
tions targeted T-cell epitopes, we demonstrate that reduced con-
formational stability and protease resistance were responsible for
the reduced antibody titer. Analysis of mouse T-cell responses cou-
pled with biophysical studies on single-substitution versions of PE-
III suggested that modest but comprehensible changes in T-cell
priming can dramatically perturb antibody production. The most
strongly responsive PE-III epitope was well-predicted by a struc-
ture-based algorithm. In summary, single-residue substitutions
can drastically alter the processing and immunogenicity of PE-III
but have only modest effects on CD4 T-cell priming in mice. Our
findings highlight the importance of structure-based processing
constraints for accurate epitope prediction.
The accurate prediction of T-cell epitopes could be used for
the deimmunization of therapeutics and allergens, as well as
the design of more effective vaccines and cancer therapies.
Computational prediction of peptide affinity for major histo-
compatibility complex (MHC)2 antigen–presenting proteins
has become more accurate with the accumulation of peptide-
binding data and application of machine learning, but progress
has not uniformly advanced to epitope prediction (1, 2). CD4
helper T-cell epitope– containing peptides are displayed by
MHC class II molecules (MHCII) and are mostly derived from
exogenous antigens that simultaneously encounter proteolytic
enzymes and MHCII molecules in the endosomal pathway
(3, 4). CD8 cytotoxic T-cell epitope-containing peptides are
mostly derived from endogenous antigens that are processed by
the cytoplasmic proteasome and subsequently loaded into
MHC class I molecules (MHCI) in the endoplasmic reticulum
(5). Although peptide–MHCI-binding affinity is a strong pre-
dictor for CD8 T-cell epitopes, peptide–MHCII-binding
affinity is a weak predictor for CD4 T-cell epitopes in many
antigens (1, 6 –9). Previous work by our laboratory has shown
that the antigen three-dimensional structure influences antigen
processing in the endosomal pathway and therefore the selec-
tion of peptides that are presented by MHCII. Dominant helper
T-cell epitopes were found to overlap flexible loops between
elements of secondary structure and between protein domains
(10 –14). Flexible protein segments can more easily conform to
protease active sites and are ideal sites for proteolytic cleavage.
With this knowledge, we have developed an epitope-prediction
algorithm that predicts immunogenicity with significant accu-
racy (15) without consideration of peptide–MHCII-binding
affinity.
In this paper we present our studies on domain III of exo-
toxin A from Pseudomonas aeruginosa (PE) as a model antigen.
Exotoxin A has been studied for decades as a potential cancer
therapy in the form of a recombinant immunotoxin (RIT) (16,
17). In its original form, the exotoxin A RIT contained a portion
of domain I and the entirety of domains II and III of exotoxin A
linked to a cancer-specific antibody fragment (Fab). The
recombinant protein is administered to patients intravenously,
where it binds to cell-surface proteins, is internalized, and
results in cell death via ADP-ribosylation of elongation factor 2
(18). Clinical trials proved challenging, as the bacterial compo-
nent of the PE RIT is strongly immunogenic, resulting in the
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induction of neutralizing antibodies after as little as one treat-
ment, rendering the therapy ineffective (19). CD4 T-cell
responses are required for the induction of potent antibody
responses, so human CD4 T-cell epitopes within PE were
silenced by removing unnecessary segments, including most of
domain II, and introducing six amino acid substitutions within
domain III. The resulting immunotoxin, RIT-T18, induced a
smaller CD4 T-cell response from human cells (20) and a
reduced CD4 T-cell and serum antibody response in mice
(21, 22). The mutations introduced to exotoxin A domain III
(PE-III) were designed to reduce the affinity of epitope-contain-
ing peptides for the MHC class II molecule while maintaining
the structure and enzymatic activity of PE-III (22). The success-
ful “deimmunization” of PE-III provides an opportunity to use
both the WT and deimmunized PE-III as model antigens to
more finely probe the relationship between antigen structure
and antigen processing/presentation to CD4 T cells.
To that end, we purified the wildtype (WT) PE-III, T18 PE-III,
and two single mutant variants of PE-III to study how these muta-
tions have altered the structure, processing, and immune
response. We observed that the deimmunizing mutations signifi-
cantly altered PE-III stability and susceptibility to antigen-pro-
cessing proteases. The mutations also modified presentation of
epitope-containing peptides and CD4 T-cell epitope immuno-
genicity, as well as serum antibody levels in mice. We also observed
that a single mutation was sufficient to reduce serum antibody
titers below that observed for the six-mutant T18 while causing
only modest changes in the priming of CD4 T cells.
Results
WT PE-III and all mutant variants used for this study were
purified from Escherichia coli grown in autoinduction media
(23), with a typical yield of 10 –15 mg/liter of culture.
Assessing the folding stability of PE-III and mutant variants
We hypothesized that the amino acid substitutions intended
to disrupt peptide–MHCII interactions have instead altered the
conformational stability of PE-III. To test this, we first used
homology modeling and the GROMACS96 software suite to
estimate changes in the free energy of PE-III folding caused by
individual epitope-silencing mutations (Fig. S1) (24). Based on
the GROMACS software calculations, we predicted decreases
in free energy for PE-III variants containing the R427A, R494A,
and R505H mutations and an increase in free energy for PE-III
L477H and L552E mutations. We selected the R494A and
L552E single mutations for further study, as they were pre-
dicted to have opposing effects on PE-III stability and were not
located in any previously mapped mouse epitopes (20). We also
analyzed the regional stabilities of WT PE-III using the
COREX/best algorithm to generate a structural thermody-
namic ensemble (25). The COREX/best residue-specific stabil-
ities were compared with results calculated for R494A and
L552E single-mutant variants. We observed changes in pre-
dicted stability of protein substructures located near previously
identified T-cell epitopes (data not shown), as well an overall
decrease in stability for the R494A variant and an overall
increase in stability for the L552E variant. Based on the GRO-
MACS and COREX analyses, we predicted that WT, T18, and
the single-mutant PE-III R494A and L552E variants would
exhibit differences in folding stability. We next measured fold-
ing stability of purified PE-III variants using acid- and denatur-
ant-induced unfolding (Fig. 1, A and C). From the acid unfold-
ing data, EC50 values were determined for each mutant PE-III
variant using a sigmoidal dose–response regression model (Fig.
1B). The single mutant variant L552E unfolded at a significantly
lower pH value than WT PE-III, whereas R494A unfolded at a
significantly higher pH value. T18 PE-III exhibited no differ-
ence in acid-induced unfolding when compared with WT PE-
III. Free energies of unfolding were determined by fitting the
denaturant-induced unfolding curves as described previously
(14, 26). The measured free energy of unfolding for T18 PE-III
did not differ from that for WT PE-III, whereas the single
mutant variants exhibited significant changes in measured free
energy compared with WT PE-III (Fig. 1D). Our findings that
the single mutant variants R494A and L552E exhibited
decreased and increased resistance to unfolding, respectively,
matched our predictions from computational techniques.
Structural characterization of deimmunizing PE-III mutations
We have demonstrated that some single-amino acid substi-
tutions intended to deimmunize PE-III have altered the
protein’s stability and resistance to unfolding. We next sought
to explain these changes by observing the effects of these muta-
tions on the crystallographic structure of PE-III. To date, we
have been unable to crystallize PE-III R494A or T18, but we
have obtained diffraction-quality crystals of a variant of T18
lacking the L477H mutation (T18-H477L). A high-resolution
structure for WT PE-III is also already available (PDB code
1XK9) (27). Using the WT PE-III structure as a search model,
we solved the structure of PE-III T18-H477L by molecular
replacement at a resolution of 1.47 Å. Statistics and software
information are detailed in Table S1. In the WT PE-III struc-
ture, we observed arginine 494 participating in a hydrogen
bond with glutamate 445 (Fig. 2A). When alanine is substituted
for arginine 494 in T18-H477L, this interaction is eliminated,
and glutamate 445 changes conformation to a more solvent-
exposed position. Elimination of this hydrogen bond pair coin-
cided with a large increase in the crystallographic B-factors for
the loop spanning residues 480 – 496 (Fig. 2, B and C). The
replacement of leucine 552 with glutamate in T18-H477L
introduces a new hydrogen bond between glutamate 552 and
arginine 513 (Fig. 2A). In WT PE-III, arginine 513 is more than
5.0 Å away from the nearest amino acid side chain or backbone
carbonyl, too far to be participating in any meaningful struc-
tural interactions. The introduction of this hydrogen bond pair
is not accompanied by a change in B-factors (Fig. 2B). In a
structural analysis using the COREX algorithm described
above, we observed contrasting effects of the R494A and L552E
mutations on residue stabilities that are consistent with the
structural changes introduced by these mutations (Fig. 2D).
Residue stabilities were drastically decreased in the region
where the R494A mutation eliminates the hydrogen bond,
although they were noticeably increased in the region where the
L552E mutation introduces a hydrogen bond. These data dem-
onstrate that the R494A and L552E mutations have modified
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the structure of PE-III, resulting in significant changes in fold-
ing free energy and acid resistance.
Destabilizing PE-III mutations increase proteolytic
susceptibility
The presentation of antigen peptides bound to class II MHC
molecules depends on proteolytic processing of those antigens.
Previous work from our laboratory has demonstrated that the
proteolytic processing of antigens preferentially occurs at sites
within and between protein domains that are flexible, solvent-
accessible, and lacking in secondary structure (11–14, 28).
These regions are readily accessible for interactions with pro-
teases and can easily conform to protease active sites, making
them the initial sites of proteolytic cleavage within an antigen.
Furthermore, previous studies have shown that protease-resist-
ant antigens are more immunogenic than their protease-sensi-
tive counterparts (29 –31). Therefore, we predicted that prote-
olysis of PE-III initiates in flexible, unstructured regions of the
protein and that mutations would alter PE-III susceptibility to
proteolytic degradation according to changes in PE-III stability
(32). To test these hypotheses, we first performed limited
proteolysis using a single protease, proteinase K. Proteolysis
experiments were conducted over a pH range from 7.6 to 4.6 in
intervals of 1 pH unit to simulate the environment of the
antigen-processing compartment. Degradation of WT PE-III
by proteinase K at pH 7.6 is rapid and produces few fragments
(Fig. 3A). As the pH decreases, larger PE-III fragments accumu-
late, whereas the activity of the protease remains consistent to a
pH as low as 4.6, indicating that PE-III becomes more resistant
to proteolysis by proteinase K at low pH (Fig. 3A). To identify
the initial proteinase K cleavage sites, we isolated the two larg-
est fragments (18 and 15 kDa, Fig. 3A) from an SDS-polyacryl-
amide gel, digested them with trypsin, and sequenced the pep-
tides using LC and tandem MS (LC-MS/MS). High-scoring
tryptic peptides from both fragments aligned to the C-terminal
region of PE-III suggesting the cleavage sites are located within
the N-terminal region (Table S2 and Fig. 3C). Sequenced tryptic
peptides and molecular-weight estimations indicated that pro-
teinase K generated the C-terminal 18-kDa fragment by cleav-
age within the segment of residues 456 – 462 and the C-termi-
nal 15-kDa fragment by cleavage in the segment of residues
490 – 496 (Fig. 3C). To confirm the location of these preferen-
tial cleavage sites, we generated a variant of WT PE-III in which
residues 485– 492 (PE-III 485– 492) were replaced by a
histidine– glycine linker to inhibit proteolysis at this site.
Although the deletion did not entirely block proteolysis, it did
reduce cleavage of intact PE-III, increase the accumulation of
the 18-kDa fragment, and decrease the accumulation of the
15-kDa fragment. These data show that initial proteolytic
cleavage of PE-III preferentially occurs at two unstructured
loops within the protein. These two regions also have the high-
est B-factors measured from the crystal structures of WT and
T18-H477L, respectively (Fig. 2, B and C).
We next performed limited proteolysis of PE-III with cathep-
sin S, an important antigen-processing enzyme (3). As seen
with proteinase K, PE-III becomes more resistant to proteolysis
by cathepsin S as the pH decreases to pH 4.6, when PE-III
begins to unfold (Figs. 4A and 1B). Three major fragments of 18,
15, and 13 kDa were subjected to tryptic sequencing (Table S2).
Figure 1. Deimmunizing mutations alter the folding stability of PE-III. A, acid-induced denaturation of PE-III reported by Bis-ANS fluorescence (n  3). B,
analysis of best-fit pH 50 values; error bars indicate standard error; asterisks indicate significance by one-way ANOVA (*, p  0.05; **, p  0.01; ***, p  0.001; ****,
p  0.0001). C, chemical denaturation of PE-III using GdnHCl and reported by intrinsic tryptophan fluorescence (representative of n  3). The ratio of the
intensity at a given [GdnHCl] to that at zero [GdnHCl] was plotted for each concentration, and the data were fitted to equations that solve for the free energy
of unfolding at zero [GdnHCl] (G0). D, analysis of G0 values determined in C. Error bars indicate standard error, and asterisks indicate significance by one-way
ANOVA.
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The identities of tryptic peptides and molecular-weight estima-
tions indicated that cathepsin S cleaved PE-III in the region of
residues 456 – 462 to generate the C-terminal 18-kDa fragment,
residues 514 –518 to generate the N-terminal 15-kDa fragment,
and residues 527–531 to generate the N-terminal 13-kDa frag-
ment (Fig. 4A). The locations of these sites were corroborated
by cathepsin S digestion of PE-III 485– 492, in which essen-
tially the same N-terminal fragments were observed but shifted
down in molecular weight, as expected for a reduction in size
corresponding to the 486 – 492 deletion (Fig. 4C).
Proteinase K is not associated with antigen processing, and
although cathepsin S is an important antigen-processing enzyme,
the lysosome contains a variety of exo- and endoproteases capable
of participating in antigen processing (3). Therefore, we sought to
more accurately assess differences in proteolytic processing using
lysosomal extracts from a mouse macrophage cell line, RAW264.7
(29). PE-III variants were incubated with lysosomal extracts in pH
conditions corresponding to the early (pH 5.9), mid (pH 5.2), and
late (pH 4.5) lysosomal environments (Fig. 4D) (31). At the highest
pH condition, no degradation was detected for PE-III WT or
L552E, whereas R494A and T18 were substantially degraded by
24 h. These differences were exaggerated at pH 5.2, as both PE-III
R494A and T18 were completely degraded by 24 h, whereas little
proteolysis was detected for WT PE-III and L552E. At the lowest
pH condition, WT PE-III and L552E persisted for up to 12 h, while
R494A and T18 were completely degraded by 6 h. Thus, we con-
cluded that WT and L552E are much more resistant to lysosomal
proteases than R494A and T18 across various pH conditions.
Proteolysis with proteinase K of the WT and three mutant
PE-III variants at decreasing pH values revealed differences in
the accumulation of specific fragments such as the C-terminal
15-kDa fragment mentioned above. These differences were
most obvious at pH 5.6 where accumulation of the C-terminal
15-kDa fragment is greatest (Fig. 3B). In the condition with the
least protease present, there was as much or more degradation
of PE-III variants, compared with that of WT PE-III (Fig. 3D).
Figure 2. Deimmunizing mutations alter the structure of PE-III. A, orientation of residues at the 494 and 552 positions in the WT (green, PDB code 1XK9) and
T18-H477L (cyan, PDB code 6EDG) structures. B, Comparison of the crystallographic B-factors from the WT and T18-H477L structures. Arrows indicate locations
of the R494A and L552E mutations. C, approximate locations of the proteinase K cleavage sites within the WT PE-III structure. D, COREX stability constants of the
WT and T18-H477L structures. Arrowheads indicate locations of the R494A and L552E mutations.
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However, accumulation of the C-terminal 15-kDa fragments
was significantly reduced for the PE-III variants R494A and
T18, suggesting that the mutant fragments were more sensitive
to proteolysis than the WT or L552E fragments (Fig. 3E). A
similar pattern of proteolytic susceptibility and fragment accu-
mulation was also observed for cathepsin S proteolysis (Fig. 4B),
suggesting that proteolysis by both model proteases and lyso-
somal proteases is directed by the structure of the substrate.
Deimmunizing mutations alter the processing and
presentation of stabilized PE-III variants in antigen-presenting
cells
Peptides derived from the lysosomal processing of protein
antigens must be bound to the peptide-binding regions of MHC
class II molecules before they are displayed to CD4 T cells on
the surface of antigen-presenting cells. Because the deimmu-
nizing mutations have altered PE-III stability and proteolytic
processing, we hypothesized that the mutations would alter the
spectrum of PE-III– derived peptides displayed by antigen-pre-
senting cells, as modeled by the macrophage-like RAW264.7
cell line. Previous studies have used immunoprecipitation to
isolate solubilized peptide–MHC complexes and then identify
peptide sequences using biochemical techniques, including MS
(33, 34). However, immunopurification has several weaknesses
that limit its usefulness for MHC class II ligand interrogation.
The purification of peptide–MHCII complexes results in a
large amount of sample loss and thus requires a very large
(108) number of cells; there also appears to be a bias toward
Figure 3. Limited proteolysis of PE-III variants demonstrates folding stability influences proteolytic susceptibility. A, limited proteolysis of WT PE-III
with proteinase K (Prot K). The indicated amount of protease was incubated with WT PE-III for 15 min at 37 °C at the indicated pH prior to analysis by SDS-PAGE
and Coomassie staining. Arrowheads indicate the fragments selected for analysis by MS. B, limited proteolysis of PE-III variants with proteinase K at pH 5.6.
Arrowheads indicate the bands analyzed in D (top) and E (bottom). C, limited proteolysis of WT and 485– 492 PE-III with proteinase K at the indicated pH.
Arrowheads indicate locations of proteinase K cleavage sites in either variant detected by MS. D, mean relative quantity of the intact PE-III variant after
proteolysis with 0.5 g of proteinase K as compared with the undigested lane. Error bars indicate standard deviation (n  3). E, mean relative quantity of the
major 15-kDa fragment of PE-III variant after proteolysis with 0.5 g of proteinase K, as compared that of WT PE-III. Error bars indicate standard deviation, and
asterisks indicate significance by one-way ANOVA (n  3).
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the identification of high-affinity peptides that selectively
remain bound to the MHCII molecule during the purification
process (35). To mitigate these issues, we utilized mild-acid
elution to strip peptides from the surface of antigen-presenting
cells that have been incubated with PE-III or its mutant variant
(36, 37). Eluted peptides were then purified and subjected to LC
and tandem MS (LC-MS/MS) for identification (Fig. 5A). We
considered only peptides of 12 residues or longer to eliminate
the possibility that they were associated with MHCI. Typically,
1–2% of the identified peptides were derived from PE-III, and
they formed nested clusters whose members differed by at most
a few residues, typical of MHCII-bound peptides (Fig. 5B). Pep-
tides detected by this method could not be positively identified
as MHCII ligands, but they were derived from PE-III that had
been internalized to subcellular compartments that are associ-
ated with antigen processing and normally contain MHCII
molecules (Fig. S2). Peptides eluted from cells fed WT, R494A,
or L552E were similar in diversity, except for a cluster of pep-
tides centered around the site of the L552E mutation. This clus-
ter was completely absent from samples obtained from cells fed
PE-III T18. Overall, less diversity in peptides was observed from
cells fed PE-III T18. The most densely populated peptide clus-
ters were centered on, or adjacent to, regions of high-solvent
accessibility (Fig. 5C). Two large clusters centered around res-
Figure 4. Destabilized PE-III variants are more susceptible to proteolysis by lysosomal proteases. A, indicated amount of cathepsin S was incubated with
WT PE-III for 3 h at 37 °C at the indicated pH prior to analysis by SDS-PAGE and Coomassie staining. Arrowheads indicate fragments selected for analysis by MS.
B, limited proteolysis of PE-III variants by cathepsin S at pH 5.6 for 3 h at 37 °C. C, C-terminal cleavage sites were confirmed by limited proteolysis of a PE-III variant
lacking the 490s loop mentioned above. Schematic showing the locations of the cathepsin S cleavage sites within the primary structure of PE-III is placed below
the gel. D, proteolysis of the PE-III variants using lysosomal extracts at different pH values analyzed by SDS-PAGE and Coomassie staining.
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idues 450 and 480 were located adjacent to highly solvent-ac-
cessible regions of PE-III that serve as preferred protease-cleav-
age sites (Fig. 5C).
Destabilizing PE-III mutations reduce serum antibody
response with minor changes to CD4 T-cell priming
The amino acid substitutions originally made to the full-
length recombinant immunotoxin were intended to disrupt
peptide binding to MHC class II, and the resulting mutant
immunotoxin T18 elicited significantly reduced CD4 T-cell
and serum-antibody responses in immunized mice (21). We
next sought to replicate these findings using PE-III variants. We
began with weekly intravenous administrations to BALB/c
mice to mimic clinical treatment with RIT in the absence of any
adjuvant. After 4 weeks, mice immunized with PE-III WT or
L552E had elevated PE-III–specific serum IgG, whereas PE-III
T18 induced a significantly reduced serum IgG response (Fig.
6A and Fig. S3). PE-III R494A immunization induced a drasti-
cally reduced serum IgG response compared with WT PE-III
and PE-III T18. Next, we performed CD4 T-cell epitope map-
ping with a separate group of mice, following a single immuni-
zation with PE-III variants and double-mutant heat-liable
E. coli enterotoxin (R192G/L211A) as adjuvant (38). To restim-
ulate PE-III–specific CD4 T cells, we used a set of 21 overlap-
ping 20-residue peptides with a 10-residue offset (Table S3).
We detected responding T cells by IL-2 ELISpot and identified
epitopes using the Wilcoxon signed-rank test. Peptides that
passed the Wilcoxon test and generated an average of 20 spots
per mouse or greater were considered epitopes. CD4 T cells
from mice immunized with WT PE-III responded strongly to
Figure 5. In vitro processing and presentation of PE-III variants generate nested clusters of peptides. A, schematic for the mild acid elution workflow.
Antigen-presenting cells are incubated with PE-III protein for 6 h before peptides are eluted with acid and analyzed by LC-MS/MS. B, eluted peptides detected
by MS aligned to the PE-III sequence (black lines). Numbered red lines indicate PE-III epitopes reported here. C, solvent-accessible surface area determined from
the WT PE-III structure (PDB code 1XK9) variant aligned to the graph in B. Red arrowhead indicates approximate locations of proteinase K cleavage site; blue
arrowheads indicate approximate locations of cathepsin S cleavage sites, and the green arrowhead indicates a shared proteinase K (Prot K) and cathepsin S (Cat
S) cleavage site.
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peptides 2, 3, 8, 14, 15, and 16 (Fig. 6B). All groups of mice
responded to peptides 3 and 14, and particular groups
responded variously to peptides 2, 4, 8, 13–15, and 19 (Fig. 5B,
red lines, and Table 1). All epitope-mapping observations are
summarized in Table 1. Peptide sequences matching mapped
epitopes were also observed in the sets of peptides eluted from
antigen-presenting cells. Interestingly, the CD4 T-cell
responses to peptides 15 and 16 were absent from mice immu-
nized with PE-III T18, and the peptide cluster containing pep-
tides 15 and 16 was absent from the eluate of cells fed PE-III T18
(Figs. 5B and 6B). However, the appearance of a response to
peptide 8 exclusively in WT-immunized mice was not consis-
tent with elution results, as peptides overlapping peptide 8 were
observed in all elution experiments, regardless of the antigen
administered (Figs. 5B and 6B).
Discussion
In this study we tested the following hypotheses: (i) the
epitope-silencing mutations made to domain III of Pseudomo-
nas exotoxin A (PE-III) have altered the structure and stability
of the protein, and (ii) these changes are responsible for the
reported reduction in CD4 T-cell and serum antibody
responses in the corresponding therapeutic immunotoxins
(19 –22). We also identified previously unreported CD4
T-cell epitopes in mice. Earlier work has shown that antigens
resistant to unfolding and proteolysis are much more immuno-
genic than antigens with the same three-dimensional structure
but are less stable and more susceptible to proteolysis (29, 30).
Others have also proposed models for antigen processing in
which there is an ideal level of protein conformational stability
for antigen processing (31). Unstable antigens are degraded too
quickly to be loaded onto class II MHC molecules; and for an
excessively stabilized antigen, processing occurs too slowly for
peptide–MHCII complexes to be generated. Here, we have
examined the effects of two single epitope-silencing mutations
as well as the combination of six deimmunizing mutations on
the stability, proteolytic processing, presentation, and immu-
nogenicity of epitope-containing peptides of PE-III.
We observed that the mutations altered PE-III structure and
stability and that individual mutations can reduce or enhance
serum-antibody response in immunized mice. The mutations
were designed to reduce the affinity of epitope-containing pep-
tides for the MHCII molecule (20). Our results show that all
PE-III variants examined here are capable of priming T cells,
and thus the disruption of peptide–MHC interactions alone
cannot explain the reduced antibody response to certain PE-III
variants. An earlier epitope-mapping study identified domain II
Figure 6. Deimmunized PE-III variants induce lower antibody titers but
effectively prime CD4 T cells. A, BALB/c mice were immunized i.v. for 4
weeks, and serum samples were taken 4 days after each immunization. PE-III–
specific antibodies were detected by direct ELISA. Each line indicates average
titer as logEC50 determined by nonlinear regression. Error bars indicate stan-
dard error; asterisks indicate significance by one-way ANOVA (n  8 per
group). Data are representative of three independent experiments. B, BALB/c
mice were immunized once intranasally with PE-III and dmLT. Spleens were
isolated, and splenocytes were restimulated with peptides spanning the
sequence of WT PE-III with mutant peptides substituted as necessary in dupli-
cate. Bars show average spot-forming units (SFU) per 5  105 cells. Error bars
indicate standard deviation; asterisks indicate significance by the Wilcoxon
signed-rank test, and a mean SFU greater than 20. Dashed line indicates an
SFU value 2 S.D. over background.
Table 1
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of the WT immunotoxin as the most immunogenic domain and
showed that several mice responded weakly to peptides corre-
sponding to peptides 4 and 5 used in this study. The deimmu-
nized immunotoxin elicited a very weak T-cell response to a
single peptide, approximately corresponding to peptide 3 used
in this study (21). However, there are several important differ-
ences between the previous and current studies, such as the
route and frequency of immunization, as well as the antigen
dose and adjuvant used. Regardless of these differences, we
have reinforced the identification of the region covered by pep-
tides 2– 4 as the most immunogenic and have identified other
epitopes that had not been reported.
The overall native conformation of PE-III was not disrupted
by either of the two single-residue substitutions or the combi-
nation of all six residue substitutions. All four PE-III proteins
exhibited cooperative unfolding transitions when treated with
acid or chemical denaturant (Fig. 1). However, the single-resi-
due substitutions shifted conformational stability in different
directions. Using X-ray crystallography of the five-residue sub-
stituted T18-H477L, we determined that the changes in stabil-
ity resulting from the R494A and L552E substitutions were
likely due to the removal and addition of a hydrogen bond,
respectively (Fig. 2A). These changes in hydrogen bonds were
also reflected in the crystallographic B-factors and stability
analysis obtained from the COREX algorithm (Fig. 2, B and D),
which show that the R494A substitution caused a substantial
increase in flexibility in the 490s loop. The L552E mutation had
no discernable effect on B-factors but did cause a modest
increase in COREX residue stabilities in the region of the muta-
tion. The structural effects of the other three mutations
(R427A, F443A, and R505H) were unclear, as Arg-427 and Arg-
505 interact almost exclusively with solvent, whereas the F443A
mutation appears to alter hydrophobic interactions, the effects
of which are difficult to analyze. However, it is possible that
these additional mutations within T18-H477L also contribute
to the structural differences observed between WT PE-III and
T18-H477L.
Our previous work has shown that flexible regions within
and between protein domains are the favored sites for proteo-
lytic cleavage and that the terminal segments of early pro-
cessing intermediates provide CD4 T-cell epitopes (10 –14,
28, 39). In this study, we observed that proteolysis of PE-III with
proteinase K produces two major fragments resulting from
cleavage within the 460s loop and 490s loop (Fig. 3). These two
loops are characterized by a lack of secondary structure, low
COREX stability factors, high-crystallographic B-factors, and
high-solvent accessibility, which are all indicative of flexibility
and promote proteolytic susceptibility. Interestingly, PE-III
became less sensitive to proteolysis at pH 6.6 and 5.6 and then
resumed sensitivity at the pH of the global unfolding transition
(pH 4.6, Fig. 1B). Likewise, at reduced pH, the two major pro-
teinase K fragments accumulated, suggesting they had become
more resistant to further proteolysis. Of potential interest to
PE-III immunology, these fragments appeared to be much less
resistant to proteolysis in the deimmunized PE-III variants
R494A and T18, suggesting that a similar processing interme-
diate may have become a poorer source of one or more T-cell
epitopes. Indeed, the epitopes contained in peptide 16 (and to a
lesser extent peptide 15) were less immunogenic in PE-III vari-
ants R494A and T18. Whether a proteinase K-like enzyme par-
ticipates in antigen processing is unknown. Aside from the
well-studied lysosomal enzymes, the secretory-pathway serine
proteases have been implicated in antigen processing (40, 41).
We observed a similar pattern of limited proteolysis by the
authentic antigen-processing enzyme, cathepsin S. As the pH is
reduced to pH 5.6, intact WT PE-III becomes more resistant to
proteolysis by cathepsin S, and a fragment resulting from cleav-
age at the 460s loop accumulates (Fig. 4A). This same fragment
accumulates even further in the cathepsin S digestion of stabi-
lized mutant L552E. In the immune response, the epitope con-
tained in peptide 16 was dramatically reduced in both L552E
and T18 (which contains the L552E mutation). Because pep-
tides corresponding to peptide 16 were absent or reduced from
the pool of peptides eluted from RAW264.7 cells, we speculate
that a processing intermediate is over-stabilized in variants
containing the L552E mutation and therefore is a poor source
of peptide 16. Taken together, the results with proteinase K and
cathepsin S are consistent with the accumulation of a pro-
cessing intermediate following cleavage at the 460s loop that
affects the presentation of an epitope contained in peptide 16.
This phenomenon is similar to our previous observation of a
correlation between the accumulation of a proteolytic fragment
in vitro with the presentation of an adjacent epitope to a T-cell
hybridoma in a series of engineered variants of bacteriophage
T4 Hsp10 (13).
We also observed that cathepsin-S cleaves within the C-ter-
minal region of PE-III, near the location of epitopes mapped in
this study (Fig. 5C). Cathepsin S appears to be distinct from
proteinase K, in that it cleaves efficiently in regions of moderate
flexibility and solvent accessibility (Figs. 4B and 5C), as well as
in regions of high flexibility and solvent accessibility, which is
characteristic of proteinase K (Figs. 4A and 5C).
When we subjected the PE-III variants to proteolysis by
macrophage lysosomal extracts, we observed that the R494A
and T18 variants exhibited greater proteolytic susceptibility
compared with the WT or stabilized L552E variant. These
results are consistent with previous studies that correlated
increased sensitivity to lysosomal extracts with decreased
immunogenicity in vivo (30, 31). Large proteolytic fragments
that might represent early processing intermediates were not
observed in the course of digestion with lysosomal extracts,
which we propose is due mainly to the presence of exopeptidase
activities, such as has been described for cathepsin B (42).
The deimmunization of the PE-III recombinant immuno-
toxin resulted in a significant decrease in neutralizing serum
antibodies in immunized mice (21). It was important that we
replicate the deimmunization that was previously observed for
the Fab-containing full-length RIT. The lack of domain II and
the Fab could affect pharmacokinetics and the clearance rate of
PE-III and thus the exposure time of the molecule to the
immune system. Nevertheless, the six-residue substituted PE-
III T18 induced a lower level of serum IgG in immunized mice,
consistent with previous findings (Fig. 6A) (21). Surprisingly,
the single-mutant variant R494A exhibited substantially lower
serum IgG compared with both PE-III WT and T18. Despite the
reduced antibody induced by some variants upon intravenous
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immunization, all PE-III variants tested in this study were capa-
ble of priming CD4 T cells, as detected by IL-2 ELISpot with
splenocytes following intranasal immunization with adjuvant
(Fig. 6B). Therefore, these results suggest that the deimmuni-
zation of PE-III was not achieved by the wholesale elimination
of CD4 T-cell epitopes. Nevertheless, we did observe differ-
ences in the epitope specificity of CD4 T cells primed by dif-
ferent PE-III variants.
Our observations raise the question of how the antibody
response to PE-III T18 was reduced or, in the case of PE-III
R494A, essentially eliminated, given the subtle changes in
CD4 T-cell priming observed here. Robust antibody
responses require two antigen-processing and presentation
steps, the initial priming of CD4 T cells by dendritic cells, and
later cognate peptide–MHC interactions between CD4 T
cells and antigen-specific B cells at the border between T- and
B-cell zones and in the germinal center within the lymph node
(43). It is possible that the deimmunizing mutations affect the
phenotypes of primed T cells without diminishing their num-
bers. Past work has demonstrated that the abundance of
peptide–MHC complexes and the avidity of the T-cell receptor
influence effector T-cell fate (44). Deimmunized PE-III variants
could exhibit a reduced capacity to induce T follicular helper
cells that are essential for robust antibody responses (45, 46). It
is also possible that the deimmunizing mutations modify pro-
cessing and presentation distinctively within the B cells, such
that the B cells are unable to solicit help from T follicular helper
cells. These possibilities are not mutually exclusive and may be
occurring simultaneously to disrupt the antibody response
against the deimmunized PE-III variants.
Structure-based epitope prediction captures the most
strongly immunogenic PE-III epitope but fails to accurately
predict others. The PE-III epitopes contained within peptides
2– 4 lie within the most stable region of the protein, located
near the N terminus and near a preferred protease cleavage site
within the 460s loop, and therefore it requires only a single
proteolytic event to yield the free peptide–MHCII complex.
Peptide 3 is strongly predicted to become an epitope by our
structure-based prediction algorithm, which generates a profile
of antigen processing likelihood (APL) score on the basis of
multiple types of conformational stability data (Fig. 7 and
Fig. S4) (15). Peptide 3 is predicted to bind well to the I-Ad (Fig.
7) and I-Ed (Fig. S5) MHC molecules, whereas peptides 2 and 4
have poor predicted MHCII affinity, which may be responsible
for their greatly reduced immunogenicity compared with pep-
tide 3.
The epitopes within peptides 8 and 16 were the only epitopes
that were sensitive to the deimmunizing mutations made to
PE-III. The epitope in peptide 8 lies between the 460s and 490s
loops. Although peptide 8 is readily processed and accumulates
on model antigen–presenting cells (Fig. 5B), it is not strongly
predicted to be an epitope by APL, due to its relatively low
conformational stability (Fig. S4). In contrast, peptide 8 is pre-
dicted to bind to the I-Ad MHCII molecule with affinity above
the 60th percentile. An explanation for the poor immunogenic-
ity of peptide 8 in mutant PE-III variants is unclear and may be
due to divergent conformational effects, depending on the PE-
III variant used. Mice immunized with R494A may not respond
to peptide 8 because the epitope is destroyed by proteolysis
rather than presented, a hypothesis that is consistent with the
increased proteolytic susceptibility of intact R494A and its
epitope-containing fragments (Fig. 3). In contrast, mice immu-
nized with L552E or T18 may not respond to peptide 8 because
the epitope is sequestered by the stabilized structure in L552E
and T18, as has been described for particular epitopes in other
antigens (14, 47). Peptide 16 elicited a response from only mice
immunized with WT PE-III, and this may be for the same rea-
sons as noted for peptide 8. These two epitopes are located in
different -strands of the same -sheet in PE-III, which could
account for similar processing fates. The disruption of PE-III
structure by the R494A mutation causes proteolytic destruc-
tion of both peptides 8 and 16, whereas the stabilization pro-
vided by the L477H and L552E mutations reduces their pro-
cessing efficiency (Fig. 5B) (47). Peptide 16 does contain the
L552E mutation; however, this mutation results in a negligible
change in predicted binding affinity to both the I-Ad and I-Ed
MHCII molecules (data not shown) (48).
The epitopes contained within peptides 14 and 15 corre-
spond to a relatively unstable region of the protein flanked by
two very stable regions and are therefore not well predicted by
APL scores. Peptides 14 and 15 are predicted to bind to the I-Ad
MHC molecule as strongly as peptides 3 and 8. The character-
istics of high-affinity binding and location within a large unsta-
ble region are compatible with a “protease-independent” mech-
anism of presentation, in which this region of PE-III may unfold
and bind to the MHCII before the epitopes can be destroyed by
proteolysis (Fig. 5B) (49). We note that peptides 11 and 17 are
predicted to have strongly MHCII-binding epitopes and rea-
sonably favorable APL scores, but epitopes were not found. As
yet, the poorly understood mechanisms must account for their
poor immunogenicity. We are currently exploring methods to
Figure 7. Dominant mouse and human PE-III epitopes are well-predicted
by a structure-based epitope prediction algorithm. A, prediction of mouse
PE-III epitopes using structure-based processing likelihood (15), MHC-bind-
ing prediction for the I-Ad MHCII molecule, and their combination. B, predic-
tion of human PE-III epitopes using structure-based processing likelihood,
MHC-binding prediction, and their combination. Vertical lines indicate posi-
tions of experimentally mapped epitopes. Bottom tic marks represent 20 res-
idue peptides detailed in Table S3.
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account for different processing pathways to improve the pre-
dictive ability of APL.
Interestingly, the newly mapped PE-III epitopes in mice are
similar to those reported in RIT-treated human patients (pep-
tides 8 and 16, Fig. 7B) (20), suggesting that processing of PE-III
generates a set of epitope-containing peptides that are common
to mice and humans and then a subset binds to the available
MHCII molecules. The human PE-III epitopes are all well-pre-
dicted by APL, and the prediction was improved when com-
bined with MHCII affinity predicted for the allele DRB1_15, the
most common allele within the cohort used for the epitope
mapping study (20).
In conclusion, our data demonstrate that single-residue sub-
stitutions drastically altered the structure, processing, and
immunogenicity of PE-III while having modest effects on
CD4 T-cell priming in mice. The dominant mouse PE-III
epitope is well predicted by APL, whereas subdominant
epitopes are poorly predicted because they are protease-inde-
pendent or for reasons that remain obscure. These results pro-
vide new insights into the importance of structure-based pro-
cessing constraints for accurate epitope prediction and
highlight the need to combine both APL and MHCII-binding
predictions to produce a more holistic understanding of anti-
gen processing and presentation through further experimental
study.
Experimental procedures
Cloning and protein purification
Coding sequences for all four PE-III variants were codon-
optimized for E. coli and cloned by Genscript using the NdeI
and EcoRI sites of pET-22b() for lactose-inducible expression
and a C-terminal hexahistidine tag. FASTA files containing the
amino acid sequence for each variant are available in the sup-
porting information. Plasmid DNA was used to transform BL21
E. coli cells with selection by ampicillin resistance at 50 g/ml.
Protein expression was induced by culturing the cells in auto-
induction media as described in 1-liter batches at 27 °C with
shaking at 250 rpm (23). Cells were harvested by centrifugation
at 7300  g for 45 min, and cell paste was used immediately or
stored at 	80 °C. Cell paste was resuspended in purification
buffer A (50 mM Tris-HCl, pH 7.5, 25 mM NaCl), including 1
mM phenylmethylsulfonyl fluoride (PMSF), and lysed with a
French pressure cell at 16,000 p.s.i. Lysate was clarified by cen-
trifugation at 38,400  g for 30 min and filtered through cheese-
cloth. His-tagged PE-III was then purified using nickel-nitrilo-
triacetic acid affinity chromatography. Bound protein was
eluted in steps using a combination of buffer A and buffer B
(buffer A plus 250 mM imidazole) and analyzed by SDS-PAGE.
Fractions containing PE-III were pooled and further purified to
90% homogeneity by ion-exchange chromatography using
Q-Sepharose (GE Healthcare) and a gradient of buffer A and
buffer C (50 mM Tris-HCl, pH 7.5, 1 M NaCl). PE-III–
containing fractions were pooled and concentrated using Mil-
lipore Amicon ultracentrifugal filters with a MWCO of 10,000
Da. Protein for crystallization was further purified by gel filtra-
tion using a Pharmacia Superose 6 10/300 GL column and
buffer D (50 mM Tris-HCl, pH 7.5, 150 mM NaCl). Protein con-
centration was determined by absorbance at 280 nm. Purified
PE-III was aliquoted, snap-frozen in liquid nitrogen, and stored
at 	80 °C. FITC-labeled PE-III was prepared using the Fluo-
Reporter FITC protein-labeling kit (ThermoFisher Scientific)
according to the manufacturer’s instructions.
In silico stability analysis
Homology models for PE-III variants were generated using
Swiss-Model (https://swissmodel.expasy.org/) and the WT PE-
III structure (PDB code 1XK9) as a template. Homology models
were used with Swiss PDBViewer (https://spdbv.vital-it.ch/)3
(59) to perform GROMACS96 free energy calculations.
In vitro stability analysis
For acid-induced unfolding experiments, the hydrophobic
dye BIS-ANS (4,4-dianilino-1,1-binaphthyl-5,5-disulfonic
acid, Invitrogen) was used to monitor protein unfolding by fluo-
rescence spectroscopy with an excitation wavelength of 390
nm. Emissions were scanned from 400 to 500 nm. Different pH
conditions were generated using phosphate-citrate buffer,
where 0.2 M dibasic sodium phosphate and 0.1 M citric acid were
mixed until the desired pH was reached. Protein was mixed
with dye in phosphate-citrate buffer ranging from pH 7.6 to 2.6
at a concentration of 0.1 M protein and 1.0 M dye. Fluores-
cence intensities averaged for the range 476 to 485 nm and for
three replicates were analyzed by nonlinear regression using a
sigmoidal dose-response variable slope regression model
(Prism 6). For unfolding free energy determinations, 0.5 M
protein was mixed with guanidine-HCl in PBS in 0.25 M steps
from 0 to 5 M, and intrinsic tryptophan fluorescence was mea-
sured by exciting at 285 nm and scanning emissions from 300 to
400 nm. Fluorescence intensities averaged for the range 330 to
340 nm and for three replicates were analyzed by nonlinear
regression as described (14, 26). Best-fit values of pH50 and
G0 were compared using ANOVA (Prism 6).
PE-III crystallography and structure determination
After ion-exchange, PE-III was further purified using a
Superose 6 size-exclusion column (Pharmacia) and concen-
trated. Crystals were grown using the hanging-drop vapor-dif-
fusion method. The crystallization solution was prepared by
mixing on a siliconized coverslip, 2 l of protein solution (10
mg/ml PE-III 0.5 mM PJ34 (Sigma-Millipore, CAS 344458-15-
7)) with 2 l of 60% precipitation solution (0.66 M sodium cit-
rate, pH 7.5, 0.54 mM sodium azide, 0.3 mM DTT). After 24 h at
room temperature, coverslips were transferred to fresh wells
containing 100% precipitation solution (1.1 M sodium citrate,
pH 7.5, 0.9 mM sodium azide, 0.5 mM DTT) for 2–3 days at
room temperature until crystals appeared. Crystals were flash-
frozen in liquid nitrogen in a mother liquor (1.1 M citrate, pH
7.5, 0.5 mM PJ34, and 20% w/v glycerol), and diffraction data
were collected remotely at the Canadian Light Source 08ID-1
beamline. Data collection, refinement, and modeling informa-
tion are detailed in Table S1. Briefly, data were processed using
XDS/XSCALE (50), solved with molecular replacement using
3 Please note that the JBC is not responsible for the long-term archiving and
maintenance of this site or any other third party hosted site.
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the WT PE-III structure (PDB code 1XK9) (27, 51), and itera-
tively refined using refmac5 (52) within the CCP4 (53) software
suite and Coot (54).
Limited proteolysis
Proteolysis reactions with proteinase K and cathepsin S were
performed in phosphate-citrate buffer at the indicated pH.
Each 20-l reaction contained 10 g of protein and 0, 0.5, or 1.0
g of proteinase K (ThermoFisher Scientific) or 0, 0.25, or 0.5
g of recombinant human cathepsin S (Sigma-Millipore). 1 mM
DTT was included for cathepsin S proteolysis reactions. Lyso-
somal extract degradation reactions were performed in 50 mM
sodium citrate, pH 5.9, 5.2, and 4.5, plus 2 mM DTT. Each
200-l reaction contained 0.25 g/l PE-III and 0.4 g/l lys-
osomal extract. Reaction mixtures were incubated at 37 °C for
the indicated time and terminated by the addition of an equal
volume of Bio-Rad Laemmli Sample Buffer containing 5 mM
PMSF and 150 mM 2-mercaptoethanol. Samples were boiled for
5 min and then analyzed by SDS-PAGE, using a 4 –20% Bio-Rad
TGX gradient gel. Gels were stained with Coomassie Blue and
scanned on a Bio-Rad Chemidoc MP imaging system and ana-
lyzed with Bio-Rad ImageLab software. Proteolytic cleavage
sites were identified by trypsin sequencing of fragments excised
from SDS-polyacrylamide gels. Briefly, each gel slice was
destained using a 20-volume excess of 50 mM ammonium bicar-
bonate and 50% methanol for 20 min, twice. Destained gel slices
were dehydrated by incubating in a 20 volume excess of 75%
acetonitrile for 20 min. Dried slices were then incubated in a
5-volume excess of 20 g/ml MS-grade trypsin dissolved in 50
mM ammonium bicarbonate at 37 °C overnight. Each sample
was subjected to a 60-min chromatographic method employing
a gradient from 2 to 25% acetonitrile in 0.1% formic acid (ACN/
FA) over the course of 30 min, a gradient to 50% ACN/FA for an
additional 10 min, a step to 90% ACN/FA for 8 min, and a
re-equilibration into 2% ACN/FA. Chromatography was car-
ried out in a trap-and-load format using a PicoChip source
(New Objective, Woburn, MA), trap column C18 PepMap 100,
5 m, 100 Å, and the separation column was PicoChip REPRO-
SIL-Pur C18-AQ, 3 m, 120 Å, 105 mm. The entire run was 0.3
l/min flow rate. Survey scans were performed in the Orbitrap
utilizing a resolution of 120,000 between 375 and 1600 m/z.
Data-dependent MS2 scans were performed in the linear ion
trap using a collision-induced dissociation of 25%. Raw data
were searched using Proteome Discoverer 2.2 using SEQUEST.
The Protein FASTA database was Mus musculus (TaxID 
10090) version 2017-07-05 with the PE-III sequence added.
Static modifications included carbamidomethyl on cysteines
(57.021) and dynamic modification of oxidation of methio-
nine (15.9949). Parent ion tolerance was 10 ppm; fragment
mass tolerance was 0.6 Da, and the maximum number of
missed cleavages was set to 2. Only high-scoring peptides were
considered utilizing a false discovery rate (FDR) of 1%.
In vitro processing and presentation
RAW264.7 cells were cultured in RPMI 1640 medium
(Gibco) supplemented with 10% fetal bovine serum (Premium,
Atlanta Biologicals) and 1% penicillin/streptomycin (Gibco) at
37 °C and 5% CO2 in a humidified incubator.
For confocal microscopy, 1  104 cells were seeded into
cover glass chambers (ThermoFisher Scientific) and incubated
at 37 °C in 5% CO2 overnight. The next day, the growth media
were removed and replaced with fresh media containing 25
g/ml FITC-labeled WT PE-III and incubated for 30 min at
37 °C in 5% CO2. Endosomal compartments were labeled with
50 nM LysoTracker Deep Red (ThermoFisher Scientific) for 30
min at 37 °C in 5% CO2. Media were removed, and cells were
washed three times with PBS. Fluorescent images were col-
lected using a Nikon eclipse Ti2 confocal microscope with a
Plan Fluor 40 oil differential interference contrast objective.
FITC was excited at 487.7 nm, and emission was recorded at
525 nm. LysoTracker was excited at 561.4 nm, and emission
was recorded at 595 nm. Images were analyzed and processed
using NIS elements software (Nikon).
For mild acid elution, RAW264.7 cells were seeded into a
175-cm2 flask at 500,000 cells/ml and incubated until 80% con-
fluent, about 10 million cells per flask, and five flasks were used
for one experiment. PE-III WT or mutant variant was then
added to the culture medium to a concentration of 50 g/ml,
and cells were incubated for 6 h to allow for antigen uptake,
processing, and presentation. Then cells were washed three
times with 10 ml of phosphate-buffered saline (PBS, 50 mM
sodium phosphate, 125 mM sodium chloride) and incubated
with 10 ml of phosphate-citrate buffer, pH 3.2, for 5 min (36).
Phosphate-citrate buffer was prepared by mixing 0.2 M sodium
phosphate dibasic with 0.1 M citric acid until the desired pH is
reached (pH 3.2 is 40 mM dibasic sodium phosphate 80 mM
citric acid). Eluate was collected and stored at 	80 °C until
purification and analysis, and cells were washed with 10 ml PBS,
which was replaced with complete media. Cells were allowed to
recover overnight before the same process was repeated two
more times. Eluate fractions were clarified by centrifugation at
4700  g for 15 min and pooled before being applied to a Sep-
PAK (Waters) C-18 cartridge that was activated with 3 ml of
acetonitrile followed by 3 ml of ddH2O. Cartridges were washed
with 50 ml of ddH2O, and bound material was eluted using 400
l of 60% acetonitrile in ddH2O. Solvent was evaporated in a
heated speed-vac until 50 l remained, and 300 l of phos-
phate-citrate, pH 3.2, was added. Samples were analyzed imme-
diately or stored at 	20 °C until analysis. PE-III–specific pep-
tides within the eluate were identified by MS. All reagents were
purchased from ThermoFisher Scientific (Waltham, MA)
unless otherwise stated. Each sample was aliquoted and
reduced with 10 mM tris(2-carboxyethyl)phosphine for 1 h at
55 °C. Cysteines were alkylated with 20 mM iodoacetamide at
room temperature for 30 min in the dark. The protein aliquots
were desalted using a methanol/chloroform extraction (55)
before drying to completion in a speed vacuum concentrator.
The dried pellets were dissolved in 2% acetonitrile and 0.1%
formic acid. LC-MS was performed using a Dionex U3000 nano
flow system coupled to a ThermoFisher Scientific fusion mass
spectrometer. Each sample was subjected to a 90-min chro-
matographic method employing a gradient from 2 to 25% ace-
tonitrile in 0.1% formic acid (ACN/FA) over the course of 60
min, a gradient to 50% ACN/FA for an additional 10 min, a step
to 90% ACN/FA for 10 min, and a re-equilibration into 2%
ACN/FA. Chromatography and survey scans were as described
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above. Parent ion tolerance was 10 ppm; fragment mass toler-
ance was 0.6 Da, and the maximum number of missed cleavages
was set to 12, because cleavage is nonspecific. Only high-scor-
ing peptides were considered utilizing a FDR of 1%. Identified
peptides were aligned to the whole protein sequence using
Clustal Omega (https://www.ebi.ac.uk/Tools/msa/clustalo/)3
(60) and BioEdit (http://www.mbio.ncsu.edu/BioEdit/bio-
edit.html).3 Solvent-accessible surface area was calculated
using MolMol (56). Graphs and figures were made using Orig-
inPro 8 and Adobe Illustrator.
Immunogenicity of PE-III variants
Female BALB/c mice aged 6 – 8 weeks (Charles River Labo-
ratories) were used for all animal experiments. Mice were
allowed to acclimate to our facility for 1 week after arrival. For
the intravenous immunization experiments mice were admin-
istered 5 g of PE-III in 100 l of PBS weekly for 4 weeks by
retroorbital injection under 3% v/v isoflurane anesthesia and
oxygen. Four days after each immunization, serum was col-
lected by submandibular vein puncture and stored at 	20 °C.
PE-III–specific serum antibody titer was analyzed by ELISA.
Then 96-well ELISA plates (Corning) were coated overnight
with 100 l of 2 g/ml PE-III in PBS at 4 °C. Plates were then
blocked for 1 h at room temperature with 200 l of 5% w/v
nonfat dry milk (NFDM) in PBS with 0.1% v/v Tween 20
(PBST). Serum was diluted 1:10 in PBST  5% NFDM, then
serially diluted 1:5 in each column on the plate and incubated
for 2 h at room temperature. Plates were washed five times with
PBST, and IgG was detected by incubating plates with a 1:2000
dilution of goat anti-mouse IgG-HRP (Invitrogen) in PBST 
5% NFDM. Plates were washed five times with PBST and devel-
oped for 5 min with 100 l of TMB substrate (2.5 mM TMB, 3%
v/v hydrogen peroxide, 20 mM sodium acetate, pH 6.0). The
development reaction was stopped with 100 l of 0.1 M phos-
phoric acid, and absorbance at 450 nm was read using a BioTek
plate reader. Data were fit using a sigmoidal dose-response
variable–slope nonlinear regression model with the logEC50
serving as the titer and compared using ANOVA and GraphPad
Prism 6. For epitope mapping experiments, mice were immu-
nized once intranasally with 5 g of PE-III and 1 g of double-
mutant (R192G/L211A) heat-liable E. coli enterotoxin (dmLT)
as adjuvant. After 10 days, mice were euthanized by CO2
asphyxiation, and spleens were aseptically removed and
homogenized using gentle MACS C tubes (Miltenyi). Spleno-
cytes were isolated by passing the homogenate through a
40-m filter and centrifugation. Red blood cells were removed
using ACK lysis buffer (Gibco), and splenocytes were plated at a
density of 9  104 cells per well in 180 l of RPMI 1640 medium
containing 10% heat-inactivated fetal bovine serum and 1%
penicillin/streptomycin (Gibco) on microfilter ELISpot plates
(Millipore MAIPS45) precoated with anti-mouse IL-2 antibod-
ies (eBioscience). Cells were restimulated with 0.4 g of PE-III–
specific synthetic peptides (Pepscan, Netherlands), 0.04 g of
intact PE-III or dmLT, or 10 g of concanavalin A (Sigma) in
complete media to a total volume of 200 l for 36 h at 37 °C 5%
CO2. Plates were washed five times, and spots were developed
using a biotinylated secondary antibody and HRP. Spots were
counted by computer-assisted image analysis (Immunospot
5.0, Cellular Technology Ltd.). Results are shown in spot form-
ing units (SFU) per 5  105 cells. All mouse experiments fol-
lowed institutional guidelines approved by the Tulane Animal
Care and Use Committee.
Epitope prediction
Structure-based epitope prediction was performed as
described with minor changes (15). The number of proteins
homologous to PE-III is inadequate for sequence entropy to be
reliably calculated; and thus, aggregate conformational stability
was based on B-factors, solvent-accessible surface area, and
COREX/Best residue stabilities. Mapped epitopes are reported
here or previously (20). MHC binding prediction was per-
formed using the NetMHCII 2.3 server (http://www.cbs.dtu.
dk/services/NetMHC/)3 (57, 58).
Author contributions—D. L. M. and S. J. L. conceptualization;
D. L. M., R. R. M., and S. J. L. formal analysis; R. R. M. and S. J. L.
supervision; R. R. M. and S. J. L. funding acquisition; D. L. M.,
R. R. M., and S. J. L. investigation; D. L. M., H.-W. P., R. R. M., and
S. J. L. methodology; D. L. M. writing-original draft; R. R. M. and
S. J. L. project administration; D. L. M. and S. J. L. writing-review
and editing; H.-W. P. resources; R. R. M. and S. J. L. software.
Acknowledgments—We thank Jessie Guidry for assisting with the pro-
teomics work. Proteomics work was supported by National Institutes
of Health Grants P20 RR018766, P20 GM103514, and P30
GM103514 and a special appropriation from the Louisiana State
University School of Medicine Office of the Dean.
References
1. Wang, P., Sidney, J., Dow, C., Mothé, B., Sette, A., and Peters, B. (2008) A
systematic assessment of MHC class II peptide binding predictions and
evaluation of a consensus approach. PLoS Comput. Biol. 4, e1000048
Medline
2. Jensen, K. K., Andreatta, M., Marcatili, P., Buus, S., Greenbaum, J. A., Yan,
Z., Sette, A., Peters, B., and Nielsen, M. (2018) Improved methods for
predicting peptide binding affinity to MHC class II molecules. Immunol-
ogy 154, 394 – 406 CrossRef Medline
3. Watts, C. (2001) Antigen processing in the endocytic compartment. Curr.
Opin. Immunol. 13, 26 –31 CrossRef Medline
4. Latek, R. R., and Unanue, E. R. (1999) Mechanisms and consequences of
peptide selection by the I-Ak class II molecule. Immunol. Rev. 172,
209 –228 CrossRef Medline
5. Blum, J. S., Wearsch, P. A., and Cresswell, P. (2013) Pathways of antigen
processing. Annu. Rev. Immunol. 31, 443– 473 CrossRef Medline
6. Ma, C., Whiteley, P. E., Cameron, P. M., Freed, D. C., Pressey, A., Chen,
S.-L., Garni-Wagner, B., Fang, C., Zaller, D. M., Wicker, L. S., and Blum,
J. S. (1999) Role of APC in the selection of immunodominant T cell
epitopes. J. Immunol. 163, 6413– 6423 Medline
7. Gelder, C., Davenport, M., Barnardo, M., Bourne, T., Lamb, J., Askonas, B.,
Hill, A., and Welsh, K. (1998) Six unrelated HLA-DR-matched adults rec-
ognize identical CD4 T cell epitopes from influenza A haemagglutinin
that are not simply peptides with high HLA-DR binding affinities. Int.
Immunol. 10, 211–222 CrossRef Medline
8. Phelps, R. G., Jones, V. L., Coughlan, M., Turner, A. N., and Rees, A. J.
(1998) Presentation of the Goodpasture autoantigen to CD4 T cells is
influenced more by processing constraints than by HLA class II peptide
binding preferences. J. Biol. Chem. 273, 11440 –11447 CrossRef Medline
9. Kim, J., Sette, A., Rodda, S., Southwood, S., Sieling, P. A., Mehra, V.,
Ohmen, J. D., Oliveros, J., Appella, E., Higashimoto, Y., Rea, T. H., Bloom,
B. R., and Modlin, R. L. (1997) Determinants of T cell reactivity to the
Deimmunizing substitutions perturb antigen processing
















Mycobacterium leprae GroES homologue. J. Immunol. 159, 335–343
Medline
10. Landry, S. J. (1997) Local protein instability predictive of helper T-cell
epitopes. Immunol. Today 18, 527–532 CrossRef Medline
11. Dai, G., Carmicle, S., Steede, N. K., and Landry, S. J. (2002) Structural basis
for helper T-cell and antibody epitope immunodominance in bacterio-
phage T4 Hsp10. Role of disordered loops. J. Biol. Chem. 277, 161–168
CrossRef Medline
12. Carmicle, S., Dai, G., Steede, N. K., and Landry, S. J. (2002) Proteolytic
sensitivity and helper T-cell epitope immunodominance associated with
the mobile loop in Hsp10s. J. Biol. Chem. 277, 155–160 CrossRef Medline
13. Carmicle, S., Steede, N. K., and Landry, S. J. (2007) Antigen three-dimen-
sional structure guides the processing and presentation of helper T-cell
epitopes. Mol. Immunol. 44, 1159 –1168 CrossRef Medline
14. Nguyen, H.-N., Steede, N. K., Robinson, J. E., and Landry, S. J. (2015)
Conformational instability governed by disulfide bonds partitions the
dominant from subdominant helper T-cell responses specific for HIV-1
envelope glycoprotein gp120. Vaccine 33, 2887–2896 CrossRef Medline
15. Mettu, R. R., Charles, T., and Landry, S. J. (2016) CD4 T-cell epitope
prediction using antigen processing constraints. J. Immunol. Methods
432, 72– 81 CrossRef Medline
16. Kondo, T., FitzGerald, D., Chaudhary, V. K., Adhya, S., and Pastan, I.
(1988) Activity of immunotoxins constructed with modified Pseudomo-
nas exotoxin A lacking the cell recognition domain. J. Biol. Chem. 263,
9470 –9475 Medline
17. Kreitman, R. J., and Pastan, I. (1997) Recombinant toxins containing hu-
man granulocyte-macrophage colony-stimulating factor and either Pseu-
domonas exotoxin or diphtheria toxin kill gastrointestinal cancer and leu-
kemia cells. Blood 90, 252–259 Medline
18. Chaudhary, V. K., Mizukami, T., Fuerst, T. R., FitzGerald, D. J., Moss, B.,
Pastan, I., and Berger, E. A. (1988) Selective killing of HIV-infected cells by
recombinant human CD4-Pseudomonas exotoxin hybrid protein. Nature
335, 369 –372 CrossRef Medline
19. Mazor, R., Onda, M., and Pastan, I. (2016) Immunogenicity of therapeutic
recombinant immunotoxins. Immunol. Rev. 270, 152–164 CrossRef
Medline
20. Mazor, R., Vassall, A. N., Eberle, J. A., Beers, R., Weldon, J. E., Venzon, D. J.,
Tsang, K. Y., Benhar, I., and Pastan, I. (2012) Identification and elimination
of an immunodominant T-cell epitope in recombinant immunotoxins
based on Pseudomonas exotoxin A. Proc. Natl. Acad. Sci. U.S.A. 109,
E3597–E3603 CrossRef Medline
21. Mazor, R., Crown, D., Addissie, S., Jang, Y., Kaplan, G., and Pastan, I.
(2017) Elimination of murine and human T-cell epitopes in recombinant
immunotoxin eliminates neutralizing and anti-drug antibodies in vivo.
Cell. Mol. Immunol. 14, 432– 442 CrossRef Medline
22. Mazor, R., Eberle, J. A., Hu, X., Vassall, A. N., Onda, M., Beers, R., Lee,
E. C., Kreitman, R. J., Lee, B., Baker, D., King, C., Hassan, R., Benhar, I., and
Pastan, I. (2014) Recombinant immunotoxin for cancer treatment with
low immunogenicity by identification and silencing of human T-cell
epitopes. Proc. Natl. Acad. Sci. U.S.A. 111, 8571– 8576 CrossRef Medline
23. Studier, F. W. (2005) Protein production by auto-induction in high density
shaking cultures. Protein Expr. Purif. 41, 207–234 CrossRef Medline
24. Fraternali, F., and Van Gunsteren, W. F. (1996) An efficient mean solva-
tion force model for use in molecular dynamics simulations of proteins in
aqueous solution. J. Mol. Biol. 256, 939 –948 CrossRef Medline
25. Hilser, V. J., and Whitten, S. T. (2014) Using the COREX/BEST server to
model the native-state ensemble. Methods Mol. Biol. 1084, 255–269
CrossRef Medline
26. Manyusa, S., and Whitford, D. (1999) Defining folding and unfolding re-
actions of apocytochrome b5 using equilibrium and kinetic fluorescence
measurements. Biochemistry 38, 9533–9540 CrossRef Medline
27. Yates, S. P., Taylor, P. L., Jørgensen, R., Ferraris, D., Zhang, J., Andersen,
G. R., and Merrill, A. R. (2005) Structure–function analysis of water-sol-
uble inhibitors of the catalytic domain of exotoxin A from Pseudomonas
aeruginosa. Biochem. J. 385, 667– 675 CrossRef Medline
28. Mirano-Bascos, D., Tary-Lehmann, M., and Landry, S. J. (2008) Antigen
structure influences helper T-cell epitope dominance in the human im-
mune response to HIV envelope glycoprotein gp120. Eur. J. Immunol. 38,
1231–1237 CrossRef Medline
29. Delamarre, L., Pack, M., Chang, H., Mellman, I., and Trombetta, E. S.
(2005) Differential lysosomal proteolysis in antigen-presenting cells deter-
mines antigen fate. Science 307, 1630 –1634 CrossRef Medline
30. Delamarre, L., Couture, R., Mellman, I., and Trombetta, E. S. (2006) En-
hancing immunogenicity by limiting susceptibility to lysosomal proteoly-
sis. J. Exp. Med. 203, 2049 –2055 CrossRef Medline
31. Machado, Y., Freier, R., Scheiblhofer, S., Thalhamer, T., Mayr, M., Briza,
P., Grutsch, S., Ahammer, L., Fuchs, J. E., Wallnoefer, H. G., Isakovic, A.,
Kohlbauer, V., Hinterholzer, A., Steiner, M., Danzer, M., et al. (2016) Fold
stability during endolysosomal acidification is a key factor for allergenicity
and immunogenicity of the major birch pollen allergen. J. Allergy Clin.
Immunol. 137, 1525–1534 CrossRef Medline
32. Park, C., and Marqusee, S. (2004) Probing the high energy states in pro-
teins by proteolysis. J. Mol. Biol. 343, 1467–1476 CrossRef Medline
33. Karunakaran, K. P., Yu, H., Jiang, X., Chan, Q., Goldberg, M. F., Jenkins,
M. K., Foster, L. J., and Brunham, R. C. (2017) Identification of MHC-
bound peptides from dendritic cells infected with Salmonella enterica
strain SL1344: implications for a nontyphoidal Salmonella vaccine. J. Pro-
teome Res. 16, 298 –306 CrossRef Medline
34. Karunakaran, K. P., Yu, H., Jiang, X., Chan, Q., Moon, K.-M., Foster, L. J.,
and Brunham, R. C. (2015) Outer membrane proteins preferentially load
MHC class II peptides: implications for a Chlamydia trachomatis T cell
vaccine. Vaccine 33, 2159 –2166 CrossRef Medline
35. Hassan, C., Kester, M. G., Oudgenoeg, G., de Ru, A. H., Janssen, G. M.,
Drijfhout, J. W., Spaapen, R. M., Jiménez, C. R., Heemskerk, M. H., Falk-
enburg, J. H., and van Veelen, P. A. (2014) Accurate quantitation of MHC-
bound peptides by application of isotopically labeled peptide MHC com-
plexes. J. Proteomics 109, 240 –244 CrossRef Medline
36. Storkus, W. J., Zeh, H. J., Salter, R. D., and Lotze, M. T. (1993) Identifica-
tion of T-cell epitopes: rapid isolation of class I-presented peptides from
viable cells by mild acid elution. J. Immunother. Emphasis Tumor Immu-
nol. 14, 94 –103 CrossRef Medline
37. Gebreselassie, D., Spiegel, H., and Vukmanovic, S. (2006) Sampling of
major histocompatibility complex class I-associated peptidome suggests
relatively looser global association of HLA-B*5101 with peptides. Hum.
Immunol. 67, 894 –906 CrossRef Medline
38. Norton, E. B., Bauer, D. L., Weldon, W. C., Oberste, M. S., Lawson, L. B.,
and Clements, J. D. (2015) The novel adjuvant dmLT promotes dose spar-
ing, mucosal immunity and longevity of antibody responses to the inacti-
vated polio vaccine in a murine model. Vaccine 33, 1909 –1915 CrossRef
Medline
39. Dai, G., Steede, N. K., and Landry, S. J. (2001) Allocation of helper T-cell
epitope immunodominance according to three-dimensional structure in
the human immunodeficiency virus type I envelope glycoprotein gp120.
J. Biol. Chem. 276, 41913– 41920 CrossRef Medline
40. Zhu, H., Liu, K., Cerny, J., Imoto, T., and Moudgil, K. D. (2005) Insertion of
the dibasic motif in the flanking region of a cryptic self-determinant leads
to activation of the epitope-specific T cells. J. Immunol. 175, 2252–2260
CrossRef Medline
41. Schneider, S. C., Ohmen, J., Fosdick, L., Gladstone, B., Guo, J., Ametani, A.,
Sercarz, E. E., and Deng, H. (2000) Cutting edge: introduction of an endo-
peptidase cleavage motif into a determinant flanking region of hen egg
lysozyme results in enhanced T cell determinant display. J. Immunol. 165,
20 –23 CrossRef Medline
42. Bond, J. S., and Barrett, A. J. (1980) Degradation of fructose-1,6-bisphos-
phate aldolase by cathepsin B. Biochem. J. 189, 17–25 CrossRef Medline
43. Gitlin, A. D., Shulman, Z., and Nussenzweig, M. C. (2014) Clonal selection
in the germinal centre by regulated proliferation and hypermutation. Na-
ture 509, 637– 640 CrossRef Medline
44. Tubo, N. J., Pagán, A. J., Taylor, J. J., Nelson, R. W., Linehan, J. L., Ertelt,
J. M., Huseby, E. S., Way, S. S., and Jenkins, M. K. (2013) Single naive
CD4 T cells from a diverse repertoire produce different effector cell
types during infection. Cell 153, 785–796 CrossRef Medline
45. Fazilleau, N., McHeyzer-Williams, L. J., Rosen, H., and McHeyzer-Wil-
liams, M. G. (2009) The function of follicular helper T cells is regulated by
Deimmunizing substitutions perturb antigen processing
















the strength of T cell antigen receptor binding. Nat. Immunol. 10,
375–384 CrossRef Medline
46. Shulman, Z., Gitlin, A. D., Weinstein, J. S., Lainez, B., Esplugues, E., Flavell,
R. A., Craft, J. E., and Nussenzweig, M. C. (2014) Dynamic signaling by T
follicular helper cells during germinal center B cell selection. Science 345,
1058 –1062 CrossRef Medline
47. So, T., Ito, H.-O., Koga, T., Watanabe, S., Ueda, T., and Imoto, T. (1997)
Depression of T-cell epitope generation by stabilizing hen lysozyme.
J. Biol. Chem. 272, 32136 –32140 CrossRef Medline
48. Vita, R., Overton, J. A., Greenbaum, J. A., Ponomarenko, J., Clark, J. D.,
Cantrell, J. R., Wheeler, D. K., Gabbard, J. L., Hix, D., Sette, A., and Peters,
B. (2015) The immune epitope database (IEDB) 3.0. Nucleic Acids Res. 43,
D405–D412 CrossRef Medline
49. Villadangos, J. A., and Ploegh, H. L. (2000) Proteolysis in MHC class II
antigen presentation: who’s in charge? Immunity 12, 233–239 CrossRef
Medline
50. Kabsch, W. (2010) XDS. Acta Crystallogr. D Biol. Crystallogr. 66, 125–132
CrossRef Medline
51. Vagin, A., and Teplyakov, A. (1997) MOLREP: an automated program for
molecular replacement. J. Appl. Crystallogr. 30, 1022–1025 CrossRef
52. Murshudov, G. N., Skubák, P., Lebedev, A. A., Pannu, N. S., Steiner, R. A.,
Nicholls, R. A., Winn, M. D., Long, F., and Vagin, A. A. (2011) REFMAC5
for the refinement of macromolecular crystal structures. Acta Crystallogr.
D Biol. Crystallogr. 67, 355–367 CrossRef Medline
53. Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans,
P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G., McCoy, A., McNicholas,
S. J., Murshudov, G. N., Pannu, N. S., Potterton, E. A., Powell, H. R., et al.
(2011) Overview of the CCP4 suite and current developments. Acta Crys-
tallogr. D Biol. Crystallogr. 67, 235–242 CrossRef Medline
54. Emsley, P., Lohkamp, B., Scott, W. G., and Cowtan, K. (2010) Features and
development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486 –501
CrossRef Medline
55. Friedman, D. B. (2007) Quantitative proteomics for two-dimensional gels
using difference gel electrophoresis. Methods Mol. Biol. 367, 219 –239
Medline
56. Koradi, R., Billeter, M., Wüthrich, K. (1996) MOLMOL: a program for
display and analysis of macromolecular structures. J. Mol. Graph. 14,
51–55, 29 –32 CrossRef
57. Nielsen, M., Lundegaard, C., Worning, P., Lauemøller, S. L., Lamberth, K.,
Buus, S., Brunak, S., and Lund, O. (2003) Reliable prediction of T-cell
epitopes using neural networks with novel sequence representations. Pro-
tein Sci. 12, 1007–1017 CrossRef Medline
58. Andreatta, M., and Nielsen, M. (2016) Gapped sequence alignment using
artificial neural networks: application to the MHC class I system. Bioin-
formatics 32, 511–517 CrossRef Medline
59. Guex, N., and Peitsch, M. C. (1997) SWISS-MODEL and the Swiss-Pdb-
Viewer: An environment for comparative protein modeling. Electropho-
resis 18, 2714 –2723 CrossRef Medline
60. Li, W., Cowley, A., Uludag, M., Gur, T., McWilliam, H., Squizzato, S., Park,
Y. M., Buso, N., and Lopez, R. (2015) The EMBL-EBI bioinformatics web
and programmatic tools framework. Nucleic Acids Res. 43, W580 –W584
CrossRef Medline
Deimmunizing substitutions perturb antigen processing
















Daniel L. Moss, Hee-Won Park, Ramgopal R. Mettu and Samuel J. Landry
processing without eliminating T-cell epitopes
 exotoxin domain III perturb antigenPseudomonasDeimmunizing substitutions in 
doi: 10.1074/jbc.RA118.006704 originally published online January 25, 2019
2019, 294:4667-4681.J. Biol. Chem. 
  
 10.1074/jbc.RA118.006704Access the most updated version of this article at doi: 
 Alerts: 
  
 When a correction for this article is posted•  
 When this article is cited•  
 to choose from all of JBC's e-mail alertsClick here
  
 http://www.jbc.org/content/294/12/4667.full.html#ref-list-1







) on July 31, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
